Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Naiyer Rizvi
Columbia University Health Sciences, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Personal Genome Diagnostics
Intellectual property rights (e.g., royalties, patents, copyrights) not from the awardee Institution
The work of Personal Genome Diagnostics ("PGDx") is broadly related to research being carried out under this grant. The company has licensed technology of which Dr. Rizvi is a co-inventor and is entitled to a share of licensing/royalties through his previous employer (Memorial Sloan Kettering) for the use of tumor mutation burden to predict response to immune checkpoint blockade (immunotherapy efficacy). Columbia's FCOI Committee found a possibility that Dr. Rizvi’s significant financial interest in PGDx could directly and significantly affect the design, conduct or reporting of the R01.
Elucidating genetics of response to immune checkpoint blockade in lung cancer
Project Narrative Lung cancer is the most common cancer and leading cause of cancer related death worldwide, accounting for more than 1.6 million cases and 1.3 million deaths annually. The recent approvals of immune checkpoint inhibitors, nivolumab and pembrolizumab, for the treatment of non-small cell lung cancer have represented a major step forward, however little is understood as to (1) how adaptive immune resistance occurs within the tumor, (2), why only a small subset of patients respond to anti-PD-1 and (3) what are the T cells targeting at a genetic level. The leading hypothesis is that the mutation landscape is important with data now emerging from our group and others, demonstrating the mutation load is important in immune checkpoint blockade response however this needs to be studied more exhaustively. This proposal will apply new technologies to the study of response and resistance to immunotherapies in the context of a multi-disciplinary team with expertise in patient-oriented research and immune monitoring, comprehensive genetics and informatics analysis of the tumor microenvironment with state of the art validation in vitro and mouse modeling. The goals of this project are broadly to perform a deep characterization of the genetics of responders and non-responders to immune checkpoint blockade in NSCLC.
Filed on May 23, 2019.
Tell us what you know about Naiyer Rizvi's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Naiyer Rizvi filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Naiyer Rizvi | Columbia University Health Sciences | Conflict of Interest | Gritstone Oncology | $550,000 - $599,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.